HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

WCID 2025

The humanized mice transplanted with edited CCR5Δ32 hematopoietic stem cells are resistant to HIV infection

Dong S Li, Speaker at Infectious Disease Conference
YCD Biotech, China
Title : The humanized mice transplanted with edited CCR5Δ32 hematopoietic stem cells are resistant to HIV infection

Abstract:

The acquired immune deficiency syndrome (AIDS) remains to be an incurable fatal infectious disease, while several documented cases demonstrated that the patients with AIDS achieved clinically defined viral clearance following transplantation of hematopoietic stem cells with homozygous CCR5Δ32 from either bone marrow or umbilical cord blood. Unfortunately, the homozygous CCR5Δ32 genotype is found only 1% among European populations. Asian and other populations predominantly carry the wild-type CCR5 alleles. This genetic landscape underscores the urgent need for generating allogeneic homozygous CCR5Δ32 hematopoietic stem cells via gene editing. In this study, the authors engineered a CRISPR/Cas9 RNP complex incorporating in vitro-synthesized Chimera guide RNA and single-stranded homology-directed repair (HDR) templates. This complex was electroporated into human cord blood hematopoietic stem cells (CB-HSCs) using anionic polymer poly-γ-glutamic acid (PGA) as a nano-carrier. The edited CB-HSCs exhibited up to 85% efficiency of CCR5Δ32 and the loss of protein level of CCR5 is up to 92%. Upon transplantation into the immunodeficient mice, these edited CB-HSCs successfully reconstituted the hematopoietic system in mice, yielding 85%~90% CCR5Δ32 genotype in immune cells and a 94% reduction in CCR5 protein expression. Critically, the mice transplanted with edited cells are resistant to HIV infection, comparing with its wild-type CCR5 parental mice. These results raise the potential of using CRISPR/Cas9 to produce a broader resource of CCR5△32/△32 hematopoietic stem cells, which are probably curative for the patients with AIDS.

Biography:

Dr. Dong S. Li graduated from Xiang-Yale Medical College at Changsha and practiced as a neurosurgeon for 13 years before he went to UK, Canada and United States to do his post-doc, including 3 years of working at WiCell in Madison Wisconsin with Dr. James Thomson.  Dr. Li has participated several national research projects such as “973” Plan and Major Project of Science and Technology Bureau, and published several his works in the prestigious journals such as Nature Biotechnology, Nature Method, Nature Protocols, etc.  Presently, he is mainly focused on the cell-based gene therapy for AIDS.

Newsletter

By signing up, you agree to join our mailing list to receive information and updates.

Watsapp